Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.04), $0.35 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.